Capital Markets Day in Stockholm – April 25, 2018

Members of InDex’s senior management were joined by Professor Raja Atreya from the University of Erlangen-Nürnberg and Professor Walter Reinisch from the Medical University of Vienna.

Introduction

Peter Zerhouni, CEO InDex Pharmaceuticals

Ulcerative colitis – a debilitating disease with high unmet medical need

Professor Walter Reinisch, Medical University of Vienna

Cobitolimod – a promising first in class drug candidate for the treatment of ulcerative colitis

Professor Raja Atreya, University of Erlangen-Nürnberg, Principle Investigator in the CONDUCT study

The phase IIb study CONDUCT

Dr Thomas Knittel, Chief Medical Officer InDex Pharmaceuticals

Implementation of the CONDUCT study

Pernilla Sandwall, Chief Operating Officer InDex Pharmaceuticals

Cobitolimod’s market potential

Peter Zerhouni, CEO InDex Pharmaceuticals

Q&A, including Panel discussion